This is a working overview of 冻干粉, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-13. Anything still debated is marked as such rather than presented as settled.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
=== Site Master File (SMF) === A Site Master File is a document in the pharmaceutical industry which provides information about the production and control of manufacturing operations. The document is created by a manufacturer. The Site Master file contains specific and factual GMP information about the production and control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations at adjacent and nearby buildings. If only part of a pharmaceutical operation is carried out on the site, the site master file needs to describe only those operations, e.g., analysis, packaging.
==== Base Editing ==== Base editing is the third major class of rRNA modification, specifically in eukaryotes. There are 8 categories of base edits that can occur at the gap between the small and large ribosomal subunits. RNA methyltransferases are the enzymes that introduce base methylation. Acetyltransferases are the enzymes responsible for acetylation of cytosine in rRNA. Base methylation plays a role in translation. These base modifications all work in conjunction with the two other main classes of modification to contribute to RNA structural stability. An example of this occurs in N7-methylation, which increases the nucleotide's charge to increase ionic interactions of proteins attaching to the RNA before translation.
Alice in Chains performed four shows supporting the reunited original Kiss lineup on their 1996–97 Alive/Worldwide Tour, including the final live appearance of Layne Staley on July 3, 1996, in Kansas City, Missouri. Shortly after the show, Staley was found unresponsive after he overdosed on heroin and was taken to the hospital. Although he recovered, the band was forced to go on hiatus.
Sources: en.wikipedia.org
Mass spectrometry imaging (MSI) is a technique used in mass spectrometry to visualize the spatial distribution of molecules, as biomarkers, metabolites, peptides or proteins by their molecular masses. After collecting a mass spectrum at one spot, the sample is moved to reach another region, and so on, until the entire sample is scanned. By choosing a peak in the resulting spectra that corresponds to the compound of interest, the MS data is used to map its distribution across the sample. This results in pictures of the spatially resolved distribution of a compound pixel by pixel. Each data set contains a veritable gallery of pictures because any peak in each spectrum can be spatially mapped. Despite the fact that MSI has been generally considered a qualitative method, the signal generated by this technique is proportional to the relative abundance of the analyte. Therefore, quantification is possible, when its challenges are overcome. Although widely used traditional methodologies like radiochemistry and immunohistochemistry achieve the same goal as MSI, they are limited in their abilities to analyze multiple samples at once, and can prove to be lacking if researchers do not have prior knowledge of the samples being studied. Most common ionization technologies in the field of MSI are DESI imaging, MALDI imaging, secondary ion mass spectrometry imaging (SIMS imaging) and Nanoscale SIMS (NanoSIMS).
The improvement in food preservation due to refrigeration, which significantly reduced food loss and waste due to spoilage, has also led to a new supply chain infrastructure where large quantities of meat, seafood and produce can be supplied from a smaller number of farms and fisheries, both of which now output a much larger food yield per capita in comparison to the late 1800s. This has also resulted in more diversification of food products (such as rare delicacies) available to the consumer market, which has had a large impact on the nutrition, tastes and culinary arts of modern societies.
Chemical modification of wood. Wood and Fiber Sci., 26(2):270-280. Langrish, T.A.G. and Walker, J.C.F. (1993). Transport Processes in Wood. In: Walker, J.C.F. Primary Wood Processing. Chapman and Hall, London. pp121–152. Panshin, A.J. and de Zeeuw, C. (1970). Textbook of Wood Technology. Volume 1, Third Edition. McGraw-Hill, New York, 705 p. Pordage, L.J. and Langrish, T.A.G. (1999). Simulation of the effect of air velocity in the drying of hardwood timber. Drying Technology - An International Journal, 17(1&2):237-256. Rasmussen, E.F. (1988). Forest Products Laboratory, U.S. Department of Agriculture. (ed.). Dry Kiln Operators Manual. Hardwood Research Council. Rowell, R.M. (1983). Chemical modification of wood. Forest Product Abstract, 6(12):363-382. Rowell, R.M. (1991). Chemical Modification of Wood. In: Hon, D.N.-S and Shiraishi, N. (eds), Wood and Cellulosic Chemistry. pp. 703–756. Marcel Dekker, Inc., New York. Siau, J.F. (1984). Transport processes in wood. Springer-Verlag, New York. 245p. Sjostrom, E. (1993). Wood Chemistry: Fundamentals and Applications. Academic Press Limited, London. 293p. Skaar, C. (1988). Wood Water Relations. Springer-Verlag, New York. 283p. Stamm, A. J. (1964). Wood and Cellulose Science. Ronald Press, New York. 509p. Standard Australia (2000). Timber - Classification into Strength Groups. Australian/New Zealand Standard (AS/NZS) 2878. Sydney. 36p. Standard Australia (2001). Timber - Assessment of Drying Quality. Australian/New Zealand Standard (AS/NZS) 4787. Sydney. 24p. Strumillo, C. and Kudra, T. (1986).
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.